Abstract:Immune checkpoint inhibitors have garnered significant attention in oncological research over recent years. A plethora of studies have elucidated that inhibitors targeting the Programmed Death-Ligand 1 (PD-L1) play a pivotal role in circumventing the evasion mechanisms of cancer cells against the immune system. This study aimed to develop an integrated screening model combining an Artificial Neural Network (ANN), Molecular Similarity (MS) assessments, and GNINA 1.0 molecular docking, targeting PD-L1 inhibitors. A database of 2044 substances with known PD-L1 inhibitory activity was compiled from Google Patents and used to enhance molecular similarity evaluations and train the machine learning model. For retrospective validation of the docking procedure, the human PD-L1 protein, with the Protein Data Bank (PDB) ID: 5N2F, was employed as a control. In this phase of the study, 15,235 compounds from the DrugBank database were subjected to a series of screening processes: initially through medicinal chemistry filters, followed by MS assessments, the ANN model, and culminating with molecular docking using GNINA 1.0. The decoy generation yielded promising outcomes, evidenced by an AUC-ROC 1NN value of 0.52 and Doppelganger scores with a mean of 0.24 and a maximum of 0.346, indicating a high resemblance of the decoys to the active set. For MS, the AVALON emerged as the most effective fingerprint for similarity searching, demonstrating an Enrichment Factor (EF) of 1% at 10.96%, an AUC-ROC of 0.963, and an optimal similarity threshold of 0.32. The ANN model demonstrated superior performance in cross-validation, achieving an average precision of 0.863±0.032 and an F1 score of 0.745±0.039, outperforming both the Support Vector Classifier (SVC) and Random Forest (RF) models, albeit not significantly. In external validation, the ANN model maintained its superiority with an average precision of 0.851 and an F1 score of 0.790. GNINA 1.0, employed for molecular docking, was validated through redocking and retrospective control, achieving an AUC of 0.975, with a critical cnn_pose_score threshold of 0.73. From the initial 15,235 compounds, 128 were shortlisted using the MS and ANN models. Further screening through GNINA 1.0 identified 22 potential candidates, among which (3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid emerged as the most promising, with a cnn_pose_score of 0.79, a PD-L1 inhibitory probability of 70.5%, and a Tanimoto coefficient of 0.35.

VAERHNN: Voting-averaged ensemble regression and hybrid neural network to investigate potent leads against colorectal cancer

MFAE: Multilevel Feature Aggregation Enhanced Drug‐Target Affinity Prediction for Drug Repurposing Against Colorectal Cancer

SYNERGY OF ADVANCED MACHINE LEARNING AND DEEP NEURAL NETWORKS WITH CONSENSUS MOLECULAR DOCKING FOR ENHANCED POTENCY PREDICTION OF ALK INHIBITORS

Innovative Virtual Screening of PD-L1 Inhibitors: The Synergy of Molecular Similarity, Neural Networks, and GNINA Docking

Variational and Explanatory Neural Networks for Encoding Cancer Profiles and Predicting Drug Responses

Adaptive Boost Approach for Possible Leads of Triple-Negative Breast Cancer

SNPs and Blood Inflammatory Marker Featured Machine Learning for Predicting the Efficacy of Fluorouracil-Based Chemotherapy in Colorectal Cancer

An Ensemble Learning Approach for Cancer Drug Prediction

A method combining LDA and neural networks for antitumor drug efficacy prediction

Bioinformatics-based and multiscale convolutional neural network screening of herbal medicines for improving the prognosis of liver cancer: a novel approach

Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches

Overall mortality risk analysis for rectal cancer using deep learning-based fuzzy systems

Using Machine Learning Methods to Study Colorectal Cancer Tumor Micro-Environment and Its Biomarkers.

An immune-related gene prognostic prediction risk model for neoadjuvant chemoradiotherapy in rectal cancer using artificial intelligence

In Vitro Study on AI‐PRS Enabled Precision Cocktail Drugs Design for Treating Human Colorectal Carcinoma

Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis

Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial

Application of artificial intelligence in a real-world research for predicting the risk of liver metastasis in T1 colorectal cancer

DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer's Disease

Novel and versatile artificial intelligence algorithms for investigating possible GHSR1α and DRD1 agonists for Alzheimer's disease.

Unveiling NRlncRNAs as prognostic biomarkers and therapeutic targets for head‐and‐neck squamous cell carcinoma through machine learning